Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Cash (2016 - 2025)

Historic Change in Cash for Iovance Biotherapeutics (IOVA) over the last 12 years, with Q3 2025 value amounting to $25.7 million.

  • Iovance Biotherapeutics' Change in Cash rose 13978.19% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.4 million, marking a year-over-year increase of 9606.26%. This contributed to the annual value of -$59.3 million for FY2024, which is 426.09% down from last year.
  • Iovance Biotherapeutics' Change in Cash amounted to $25.7 million in Q3 2025, which was up 13978.19% from -$39.6 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Change in Cash ranged from a high of $311.8 million in Q1 2023 and a low of -$253.5 million during Q2 2023
  • In the last 3 years, Iovance Biotherapeutics' Change in Cash had a median value of -$39.6 million in 2025 and averaged -$6.7 million.
  • In the last 5 years, Iovance Biotherapeutics' Change in Cash plummeted by 27121.98% in 2024 and then skyrocketed by 23758.23% in 2025.
  • Iovance Biotherapeutics' Change in Cash (Quarter) stood at -$152.8 million in 2023, then surged by 68.27% to -$48.5 million in 2024, then soared by 152.97% to $25.7 million in 2025.
  • Its last three reported values are $25.7 million in Q3 2025, -$39.6 million for Q2 2025, and $56.0 million during Q1 2025.